GBIO: Generation Bio Co.
About
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Key Details
Market Cap
$92.84M
P/E Ratio
-0.63
1Y Stock Return
20.87%
1Y Revenue Growth
514.08%
Dividend Yield
0.00%
Price to Book
0.9
Strategies that include GBIO
Stock's related to GBIO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KN | 53.27% | $1.60B | +12.19% | 0.00% |
| TRST | 52.29% | $691.41M | +34.26% | 3.98% |
| OLP | 49.53% | $617.02M | +46.60% | 6.26% |
| SCVL | 48.43% | $914.94M | +41.95% | 1.57% |
| PHR | 47.33% | $1.07B | +20.61% | 0.00% |
| ATNM | 46.85% | $44.30M | -67.05% | 0.00% |
| RMR | 46.59% | $368.58M | -6.46% | 7.97% |
| CLDT | 46.21% | $425.53M | -12.03% | 3.24% |
| GPRO | 45.98% | $179.52M | -67.23% | 0.00% |
| NTB | 45.81% | - | - | 4.69% |
| NXDT | 45.51% | $218.01M | -37.42% | 11.58% |
| EDIT | 45.34% | $204.72M | -75.49% | 0.00% |
| ILPT | 44.79% | $253.33M | +31.62% | 1.05% |
| STHO | 44.76% | $150.51M | -5.99% | 0.00% |
| FISI | 44.32% | $408.52M | +49.41% | 4.56% |
| LAW | 44.05% | $325.90M | -3.37% | 0.00% |
| FFIC | 43.69% | $499.11M | +23.97% | 5.15% |
| GOOD | 43.69% | $758.90M | +40.97% | 6.47% |
| RICK | 43.50% | $440.11M | -13.68% | 0.51% |
| TECH | 43.42% | $10.55B | +4.49% | 0.48% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | 0.02% | $27.77B | +52.50% | 2.79% |
| GL | 0.05% | $9.18B | -8.60% | 0.86% |
| UUU | 0.16% | $4.97M | -41.89% | 0.00% |
| FATBB | -0.22% | $81.94M | -12.91% | 11.69% |
| QNTM | -0.25% | $9.19M | -94.36% | 0.00% |
| NEUE | 0.60% | $40.93M | -34.13% | 0.00% |
| SPR | 0.70% | $3.72B | +23.27% | 0.00% |
| LMT | 0.72% | $126.40B | +18.99% | 2.36% |
| LITB | 0.73% | $35.48M | -75.45% | 0.00% |
| VIRT | 0.78% | $3.17B | +110.38% | 2.60% |
| CCEC | -0.89% | $1.02B | +28.03% | 3.26% |
| PRT | -0.95% | $48.72M | -16.56% | 10.33% |
| GAN | -0.98% | $83.39M | +21.19% | 0.00% |
| TW | -1.05% | $28.66B | +42.39% | 0.29% |
| PEP | -1.13% | $215.02B | -6.60% | 3.35% |
| NNE | 1.15% | $833.66M | +531.50% | 0.00% |
| MVO | 1.30% | $106.15M | -22.78% | 16.78% |
| CYCN | -1.31% | $4.77M | -16.19% | 0.00% |
| MANU | 1.32% | $2.88B | -9.41% | 0.00% |
| T | -1.38% | $163.09B | +40.40% | 4.87% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NFLX | -16.86% | $372.45B | +83.46% | 0.00% |
| HUSA | -15.81% | $16.69M | -11.56% | 0.00% |
| CHD | -15.61% | $27.18B | +19.50% | 1.03% |
| TEM | -11.92% | $8.50B | 0.00% | 0.00% |
| PULM | -8.40% | $19.83M | +202.98% | 0.00% |
| FTNT | -8.22% | $69.59B | +72.67% | 0.00% |
| LPTH | -7.61% | $62.27M | +33.05% | 0.00% |
| BTCT | -7.00% | $42.61M | +353.33% | 0.00% |
| CME | -6.07% | $82.76B | +9.21% | 1.98% |
| CBOE | -5.64% | $21.46B | +15.84% | 1.11% |
| STG | -5.63% | $35.67M | +7.92% | 0.00% |
| VSTA | -4.66% | $204.94M | -39.33% | 0.00% |
| LUMO | -3.82% | $37.45M | +41.97% | 0.00% |
| PGR | -3.61% | $149.10B | +57.29% | 0.45% |
| MCK | -3.49% | $78.15B | +35.51% | 0.42% |
| XGN | -3.41% | $62.26M | +127.74% | 0.00% |
| ADBE | -3.24% | $219.93B | -18.23% | 0.00% |
| YY | -3.16% | $1.47B | -12.63% | 0.00% |
| SYPR | -2.98% | $32.23M | -26.32% | 0.00% |
| TCTM | -2.48% | $8.10M | -42.99% | 0.00% |
ETF's related to GBIO
News
Yahoo
Generation Bio Co. ( NASDAQ:GBIO ) just released its third-quarter report and things are looking bullish. Results...
Yahoo
Generation Bio ( NASDAQ:GBIO ) Third Quarter 2024 Results Key Financial Results Revenue: US$7.55m (up 252% from 3Q...
Yahoo
Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2024 financial results. “There is immense potential
Yahoo
As October 2024 came to a close, major U.S. indices like the S&P 500, Nasdaq, and Dow Jones Industrial Average posted losses for the month, driven by disappointing earnings from big tech companies. In light of these market fluctuations, investors may find opportunities in lesser-known areas such as penny stocks—stocks often associated with smaller or newer companies that can still offer surprising value despite their outdated moniker. By focusing on those with solid financial foundations and...
Yahoo
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.